Why there’s no Mounjaro pill
Tirzepatide has a molecular weight of approximately 4,813 daltons.1 As a general rule, molecules above 500 daltons are too large to be reliably absorbed through the gut wall.
Your stomach is designed to break down proteins and peptides into smaller amino acids.
A peptide the size of tirzepatide would be destroyed by stomach acid and digestive enzymes before enough of it could reach your bloodstream to have any effect.
Novo Nordisk solved this problem for semaglutide (the active ingredient in Wegovy) by co-formulating it with an absorption enhancer called SNAC, which temporarily protects the drug in the stomach and helps it pass through the stomach lining.4
Even with SNAC, oral semaglutide requires strict dosing conditions: an empty stomach, minimal water, and a 30-minute fast after taking it.
No equivalent absorption technology has been developed for tirzepatide. The molecule is different in structure from semaglutide, and the same approach may not work.
Eli Lilly hasn’t announced any plans to develop an oral tirzepatide formulation.
What about oral tirzepatide products sold online?
If you search for ‘Mounjaro pill’ or ‘oral tirzepatide’ online, you’ll find products sold as tablets, sublingual drops, or dissolvable pills that claim to contain tirzepatide.
These products aren’t approved by the MHRA, the FDA, or any other medicines regulator. They haven’t been tested in clinical trials, and there’s no published evidence that oral tirzepatide is effective at any dose.
In the US, some compounding pharmacies legally sold sublingual tirzepatide during a nationwide drug shortage between 2022 and 2024.
The FDA ended this practice in March 2025 after confirming that the shortage was resolved, citing safety concerns about unregulated compounded versions.5
Any product marketed as oral tirzepatide today sits outside the regulatory framework. You can’t be certain of the dose, the purity, or whether it contains tirzepatide at all.
If you want the benefits of tirzepatide, the only safe and clinically proven option is the injectable form prescribed by a registered healthcare professional.
What Eli Lilly is making instead: orforglipron
Rather than trying to make tirzepatide work as a pill, Eli Lilly has developed a different drug entirely.
Orforglipron is a once-daily oral GLP-1 receptor agonist that has completed Phase 3 clinical trials for both obesity and type 2 diabetes.3
The reason orforglipron can work as a pill is that it’s a small molecule, not a peptide. It doesn’t get broken down by digestive enzymes the way tirzepatide would.
It can also be taken at any time of day, without food or water restrictions, making it more practical than the Wegovy pill.3
In the Phase 3 ATTAIN-1 trial, orforglipron at the highest dose (36 mg) produced an average weight loss of 11.2% over 72 weeks in adults with obesity.6 Around 36% of participants at that dose achieved 15% or more weight loss.
A separate trial (ATTAIN-MAINTAIN) tested whether people who had already lost weight on injectable Wegovy or Mounjaro could maintain that weight loss by switching to oral orforglipron.
Those who switched from Wegovy regained an average of just 0.9 kg over 52 weeks, maintaining nearly all of their previous weight loss.3
Lilly submitted orforglipron to the FDA in late 2025 and has applied for a priority review, which could mean US approval as early as mid-2026.3 UK approval would follow, though no timeline has been confirmed.
Orforglipron is a GLP-1 agonist only. Unlike Mounjaro, which targets both GLP-1 and GIP receptors, orforglipron activates GLP-1 alone.
The weight loss in trials is lower than injectable Mounjaro, but it offers a convenient daily pill with no dosing restrictions.
The oral GLP-1 currently available: the Wegovy pill
The Wegovy pill (oral semaglutide 25 mg) was approved by the FDA in December 2025 and launched in the US in January 2026.2
In the OASIS 4 trial, the pill produced an average weight loss of 13.6% over 64 weeks, comparable to injectable Wegovy 2.4 mg.7
The Wegovy pill requires specific dosing conditions: it must be taken first thing in the morning on an empty stomach, with no more than 120 ml of water, and then a 30-minute wait before eating or drinking anything else.
Novo Nordisk has submitted the oral formulation to the EMA and MHRA, and UK approval is expected in late 2026.2
For a full breakdown of the Wegovy pill, including dosing, side effects, and a detailed comparison with injectable Wegovy, see our guide: The Wegovy pill: what it is, how it works, and when it’s coming to the UK.
How Mounjaro injection compares to oral GLP-1 options
|
Mounjaro (injection) |
Wegovy pill |
Orforglipron (not yet approved) |
| Active ingredient |
Tirzepatide |
Semaglutide |
Orforglipron |
| Drug class |
Dual GIP/GLP-1 agonist |
GLP-1 agonist |
GLP-1 agonist (small molecule) |
| How you take it |
Weekly injection |
Daily tablet (empty stomach, 30-min fast) |
Daily tablet (no food/water restrictions) |
| Average weight loss |
22.5% at 72 weeks (SURMOUNT-1, 15 mg)8 |
13.6% at 64 weeks (OASIS 4)7 |
11.2% at 72 weeks (ATTAIN-1, 36 mg)6 |
| UK availability |
Available now |
Expected late 2026 |
No UK timeline confirmed |
Injectable Mounjaro produces substantially greater weight loss than either of the oral options.
If maximising weight loss is your priority and you’re comfortable with injections, Mounjaro remains the most effective treatment currently available in the UK.
If needle aversion is keeping you from starting treatment, the oral alternatives offer a different route into GLP-1 therapy, with the Wegovy pill likely to be the first oral option available in the UK.
Frequently asked questions
Is there a Mounjaro pill?
No. Mounjaro (tirzepatide) is only available as a weekly injection. There is no approved oral formulation, and Eli Lilly has not announced plans to develop one.1
Can you get Mounjaro in tablet form in the UK?
No. Mounjaro is only available in the UK as a subcutaneous injection. Any product marketed as ‘Mounjaro tablets’ or ‘oral tirzepatide’ in the UK is not approved by the MHRA.
Is oral tirzepatide safe?
There are no clinical trials studying oral tirzepatide. Products marketed as oral tirzepatide online are unregulated and have not been tested for safety, effectiveness, or dosing accuracy. The FDA has warned against using these products.5
What is orforglipron?
Orforglipron is a once-daily oral GLP-1 medication being developed by Eli Lilly. It’s a small molecule (not a peptide), which means it can survive digestion.
Phase 3 trials showed an average weight loss of 11.2% at the highest dose.6 It has been submitted to the FDA for approval.
Will there ever be a Mounjaro pill?
There are no current plans to make tirzepatide available as a pill. The molecular structure of tirzepatide makes oral delivery extremely difficult.
Eli Lilly’s oral strategy is focused on orforglipron, a separate GLP-1 medication.
Is the Wegovy pill the same as Mounjaro?
No. The Wegovy pill contains semaglutide, which is a GLP-1 agonist. Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors. They are different medications made by different manufacturers.
Can I use an oral GLP-1 to maintain weight after stopping Mounjaro?
Possibly. The ATTAIN-MAINTAIN trial found that people who switched from injectable Mounjaro or Wegovy to oral orforglipron were able to maintain most of their weight loss over 52 weeks.3 Orforglipron isn’t approved yet, but this is a potential future option.
Mounjaro pill vs Wegovy pill: which is better?
There’s no Mounjaro pill. If you’re comparing Mounjaro injection to the Wegovy pill, Mounjaro produces greater average weight loss (22.5% vs 13.6%), but it requires weekly injections.
The Wegovy pill offers a needle-free alternative with lower but still clinically meaningful weight loss.78
Can you take tirzepatide orally?
Not safely or effectively. Tirzepatide is a peptide that gets destroyed by digestive enzymes.
Any oral tirzepatide products available online are unregulated and have no clinical evidence supporting their use.
When will there be a GLP-1 weight-loss pill in the UK?
The Wegovy pill is expected to receive UK approval in late 2026. Orforglipron has no confirmed UK timeline, but could be approved in 2027. Both would need NICE approval before becoming available on the NHS.
Take home message
There is no Mounjaro pill, and there are no plans to make one. Tirzepatide’s molecular structure makes oral delivery impractical with current technology.
If you want the weight-loss benefits of Mounjaro and you’re comfortable with injections, it remains the most effective GLP-1 option currently available in the UK.
If needle aversion is preventing you from starting treatment, two oral alternatives are on the way. The Wegovy pill is expected in the UK by late 2026, and Eli Lilly’s orforglipron could follow.
Both offer meaningful weight loss in a daily tablet, though neither matches the results of injectable Mounjaro.
Whichever medication you choose, the evidence consistently shows that combining GLP-1 treatment with structured lifestyle support produces better long-term results.
Second Nature’s published research found that members taking semaglutide alongside dietitian-led behaviour change support achieved an average of 19.1% weight loss at 12 months.9
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
References
- Eli Lilly. Is Mounjaro (tirzepatide) available as an oral formulation? Lilly Medical.
- Novo Nordisk. (2025). Wegovy pill approved in the US as first oral GLP-1 for weight management. Press release, 22 December 2025.
- Eli Lilly. (2025). Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy. Press release, 18 December 2025.
- Buckley, S.T., et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467).
- US Food and Drug Administration. (2025). Compounding and the FDA: questions and answers.
- Lilly. (2025). Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. New England Journal of Medicine.
- Wharton, S., et al. (2025). Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine, 393(11).
- Jastreboff, A.M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216.
- Richards, R., et al. (2025). A remotely delivered, semaglutide-supported specialist weight management program: 12-month outcomes. JMIR Formative Research, 9(1), e72577.
